340 related articles for article (PubMed ID: 27279236)
1. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Hamilton N; Marquez-Garban D; Mah VH; Elshimali Y; Elashoff D; Garon EB; Vadgama J; Pietras R
Crit Rev Oncog; 2015; 20(5-6):373-90. PubMed ID: 27279236
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
[TBL] [Abstract][Full Text] [Related]
3. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
7. Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.
Hamilton N; Márquez-Garbán D; Mah V; Fernando G; Elshimali Y; Garbán H; Elashoff D; Vadgama J; Goodglick L; Pietras R
Biomed Res Int; 2015; 2015():925703. PubMed ID: 25874233
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer.
Cetin I; Topcul M
Asian Pac J Cancer Prev; 2014; 15(6):2427-31. PubMed ID: 24761842
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
12. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
13. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N; Owusu E; Rivera G; Bandyopadhyay D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
[TBL] [Abstract][Full Text] [Related]
16. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
17. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: is there a treatment on the horizon?
Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]